View ValuationCuriox Biosystems 将来の成長Future 基準チェック /06現在、 Curiox Biosystemsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長24.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m).お知らせ • Feb 06Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea分析記事 • Oct 31Is Curiox Biosystems (KOSDAQ:445680) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m).分析記事 • Jul 16Does Curiox Biosystems (KOSDAQ:445680) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Jun 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m).Reported Earnings • Mar 25Full year 2024 earnings released: ₩503 loss per share (vs ₩702 loss in FY 2023)Full year 2024 results: ₩503 loss per share (improved from ₩702 loss in FY 2023). Net loss: ₩8.09b (loss narrowed 19% from FY 2023).New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₩6.0b revenue, or US$4.1m).お知らせ • Feb 07Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Koreaお知らせ • Jan 25Curiox Biosystems Launches Curiox C- Free Pluto ALPHA: Affordable, Hassle-Free Cell Washing AutomationCuriox Biosystems announced the launch of the Curiox C- Free Pluto ALPHA, the latest addition to the Pluto line of products. This compact and intuitive device redefines cell washing automation, bringing simplicity, reliability, and affordability to labs of all sizes. The Curiox C- Free Pluto AlphaHA replaces traditional centrifuge-based methods, offering a low-main maintenance solution that eliminates bulky hardware. Utilizing a pipette head, it delivers gentle, consistent washing of suspension cells and beads, preserving sample integrity and improving reproducibility. By simplifying workflows and reducing variability, Curiox C- Free PlutoALHA helps researchers achieve more consistent, high-quality results in less time. Key Features: Gentle Washing: Pipette-based technology ensures cell viability by avoiding centrifugation, preserving deliver cells. Effortless Integration: Compact design fits seamlessly into existing workflows, with no need for additional infrastructure. Labware Compatibility: Supports 96-well plates, deep-well plates, and Laminar Wash plates, ensuring immediate adaptability to setup. Minimal Maintenance: Virtually the same as a pipetting station, reducing downtime and operational costs for labs. Affordable Automation: Priced below $30,000, it delivers cutting-edge performance within budget-friendly constraints. Compact Footprint: Its small size ensures efficient use of valuable bench space, making it ideal for labs of all sizes. Workflow Benefits: Pre-configured with Light, Moderate, Heavy, and Ultra wash protocols, the Curiox C- Free Neptune ALPHA minimizes hands-on time for researchers, allowing them to focus on high-value tasks. The elimination of centrifugation, flicking, or resuspension steps streamlines workflows while ensuring reproducibility across experiments. These features are especially valuable for immunophenotyping, cell therapy, and drug discovery applications. Emowering Labs with the Pluto Line: The Pluto product line reflects Curiox's mission to drive innovation and enhance productivity. With a focus on scalability and adaptability, Pluto devices cater to diverse research and clinical needs. Whether for small-scale studies or industrial-scale operations, Curiox C- Free Neptune AlphaHA is a critical step in advancing automated cell washing solutions. Configurations to suit Every Need: Standard Model: Equipped with a fixed 96-channel pipette head and three plate decks, it supports wash cycles from 2 minutes onwards: tailored for precision. Custom Options: Flexible throughput with configurable pipette tips and customizable wash parameters ensures adaptability for specialized workflows.分析記事 • Dec 16Curiox Biosystems (KOSDAQ:445680) Has Debt But No Earnings; Should You Worry?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • Jul 27Curiox Biosystems Co., Ltd announced that it has received KRW 20 billion in funding from KB Securities Co.,Ltd, LS SECURITIES Co., Ltd., JB Woori Capital Co., Ltd, Kiwoom Securities Co., Ltd., KDB Capital Corp., IBK Capital Corporation and other investorsOn July 26, 2024, Curiox Biosystems Co., Ltd closed the transaction.分析記事 • Jun 20We're Not Very Worried About Curiox Biosystems' (KOSDAQ:445680) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Apr 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).New Risk • Apr 11New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.8b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩6.8b revenue, or US$5.0m).分析記事 • Mar 04We're Interested To See How Curiox Biosystems (KOSDAQ:445680) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, although... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Curiox Biosystems は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A445680 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20255,152-27,177-11,245-11,109N/A9/30/20254,258-23,247-10,366-10,111N/A6/30/20253,825-24,236-10,991-10,758N/A3/31/20253,922-9,049-10,740-10,511N/A12/31/20244,588-8,089-9,956-9,698N/A9/30/20245,967-12,372-10,209-10,159N/A6/30/20245,697-10,904-9,487-9,473N/A3/31/20246,224-10,667-8,096-7,880N/A12/31/20236,788-10,040-8,376-8,164N/A9/30/20237,113-11,594-6,723-6,298N/A3/31/20238,612-9,957-10,425-9,784N/A12/31/20227,237-11,495-10,729-9,888N/A12/31/20215,523-14,524-5,387-5,126N/A12/31/20204,384-6,279-2,849-2,661N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A445680の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A445680の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A445680の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A445680の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A445680の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A445680の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 01:59終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Curiox Biosystems Co., Ltd 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩4.3b revenue, or US$2.9m).
お知らせ • Feb 06Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 61, gasan-ro, geumcheon-gu, seoul South Korea
分析記事 • Oct 31Is Curiox Biosystems (KOSDAQ:445680) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Minor Risk Revenue is less than US$5m (₩3.9b revenue, or US$2.8m).
分析記事 • Jul 16Does Curiox Biosystems (KOSDAQ:445680) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Jun 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (₩3.9b revenue, or US$2.9m).
Reported Earnings • Mar 25Full year 2024 earnings released: ₩503 loss per share (vs ₩702 loss in FY 2023)Full year 2024 results: ₩503 loss per share (improved from ₩702 loss in FY 2023). Net loss: ₩8.09b (loss narrowed 19% from FY 2023).
New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₩6.0b revenue, or US$4.1m).
お知らせ • Feb 07Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025Curiox Biosystems Co., Ltd, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
お知らせ • Jan 25Curiox Biosystems Launches Curiox C- Free Pluto ALPHA: Affordable, Hassle-Free Cell Washing AutomationCuriox Biosystems announced the launch of the Curiox C- Free Pluto ALPHA, the latest addition to the Pluto line of products. This compact and intuitive device redefines cell washing automation, bringing simplicity, reliability, and affordability to labs of all sizes. The Curiox C- Free Pluto AlphaHA replaces traditional centrifuge-based methods, offering a low-main maintenance solution that eliminates bulky hardware. Utilizing a pipette head, it delivers gentle, consistent washing of suspension cells and beads, preserving sample integrity and improving reproducibility. By simplifying workflows and reducing variability, Curiox C- Free PlutoALHA helps researchers achieve more consistent, high-quality results in less time. Key Features: Gentle Washing: Pipette-based technology ensures cell viability by avoiding centrifugation, preserving deliver cells. Effortless Integration: Compact design fits seamlessly into existing workflows, with no need for additional infrastructure. Labware Compatibility: Supports 96-well plates, deep-well plates, and Laminar Wash plates, ensuring immediate adaptability to setup. Minimal Maintenance: Virtually the same as a pipetting station, reducing downtime and operational costs for labs. Affordable Automation: Priced below $30,000, it delivers cutting-edge performance within budget-friendly constraints. Compact Footprint: Its small size ensures efficient use of valuable bench space, making it ideal for labs of all sizes. Workflow Benefits: Pre-configured with Light, Moderate, Heavy, and Ultra wash protocols, the Curiox C- Free Neptune ALPHA minimizes hands-on time for researchers, allowing them to focus on high-value tasks. The elimination of centrifugation, flicking, or resuspension steps streamlines workflows while ensuring reproducibility across experiments. These features are especially valuable for immunophenotyping, cell therapy, and drug discovery applications. Emowering Labs with the Pluto Line: The Pluto product line reflects Curiox's mission to drive innovation and enhance productivity. With a focus on scalability and adaptability, Pluto devices cater to diverse research and clinical needs. Whether for small-scale studies or industrial-scale operations, Curiox C- Free Neptune AlphaHA is a critical step in advancing automated cell washing solutions. Configurations to suit Every Need: Standard Model: Equipped with a fixed 96-channel pipette head and three plate decks, it supports wash cycles from 2 minutes onwards: tailored for precision. Custom Options: Flexible throughput with configurable pipette tips and customizable wash parameters ensures adaptability for specialized workflows.
分析記事 • Dec 16Curiox Biosystems (KOSDAQ:445680) Has Debt But No Earnings; Should You Worry?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Jul 27Curiox Biosystems Co., Ltd announced that it has received KRW 20 billion in funding from KB Securities Co.,Ltd, LS SECURITIES Co., Ltd., JB Woori Capital Co., Ltd, Kiwoom Securities Co., Ltd., KDB Capital Corp., IBK Capital Corporation and other investorsOn July 26, 2024, Curiox Biosystems Co., Ltd closed the transaction.
分析記事 • Jun 20We're Not Very Worried About Curiox Biosystems' (KOSDAQ:445680) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Apr 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Less than 3 years of financial data is available. Revenue is less than US$5m (₩6.8b revenue, or US$4.9m).
New Risk • Apr 11New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.8b (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (₩6.8b revenue, or US$5.0m).
分析記事 • Mar 04We're Interested To See How Curiox Biosystems (KOSDAQ:445680) Uses Its Cash Hoard To GrowWe can readily understand why investors are attracted to unprofitable companies. For example, although...